ARWR Overview
Upcoming Projects (ARWR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ARWR)
-
Discussing Arrowhead's plozasiran for managing persistent chylomicronemia and pancreatitis risk with FCS after receiving FDA breakthrough therapy designation
Tickers: ARWR, IONS
Executed On: Sep 12, 2024 at 03:00 PM EDT -
Discussing the different therapeutic approaches from Fulcrum Therapeutics and Arrowhead Pharmaceuticals for the treatment of Facioscapulohumeral muscular dystrophy (FSHD)
Tickers: ARWR, RNA, FULC
Executed On: Jun 18, 2024 at 12:00 PM EDT -
Discussing Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
Tickers: ARWR, IONS
Executed On: Jun 13, 2024 at 03:00 PM EDT -
A Fresh Look at Arrowhead Pharmaceuticals' Plozasiran in Treating Hypertriglyceridemia
Ticker: ARWR
Executed On: May 03, 2024 at 03:00 PM EDT -
A Second View: Unveiling the Efficacy of Arrowhead Pharmaceuticals' Plozasiran in Treating Hypertriglyceridemia and Zodasiran in Mixed Dyslipidemia: Insights from Phase 2 Clinical Trials
Ticker: ARWR
Executed On: Dec 20, 2023 at 10:00 AM EST -
Unveiling the Efficacy of Arrowhead Pharmaceuticals' Plozasiran in Treating Hypertriglyceridemia and Zodasiran in Mixed Dyslipidemia: Insights from Phase 2 Clinical Trials
Ticker: ARWR
Executed On: Dec 12, 2023 at 11:00 AM EST -
A Second Look: Discussing the phase 2 SEQUOIA trial data on Arrowhead 's fazirsiran in treating A1AT liver disease
Ticker: ARWR
Executed On: Apr 12, 2023 at 05:30 PM EDT -
Discussing the phase 2 SEQUOIA trial data on Arrowhead 's fazirsiran in treating A1AT liver disease
Ticker: ARWR
Executed On: Mar 28, 2023 at 06:00 PM EDT -
A discussion of Fazirsiran and its potential in A1AT liver disease ahead of the phase 2 placebo controlled SEQUOIA trial
Tickers: ARWR, VRTX, INBX
Executed On: Nov 18, 2022 at 12:00 PM EST
Expired Projects (ARWR)
-
Discussing Arrowhead’s fazirsiran in Severe alpha-1 antitrypsin deficiency following recently presented Phase 2 Results
Ticker: ARWR
Execute By: Aug 31, 2022 -
A Second View: Discussing Arrowhead’s Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Ticker: ARWR
Execute By: Jul 31, 2020
Upcoming & Overdue Catalysts (ARWR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ARWR)
-
Arrowhead (ARWR) Announces Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Ticker: ARWR
Occurred on: Jul 06, 2021 -
Arrowhead Pharmaceuticals (ARWR) Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
Ticker: ARWR
Occurred on: Sep 16, 2019 -
Arrowhead Pharmaceuticals (ARWR) Makes Poster Presentations of New Data on ARC-AAT
Ticker: ARWR
Occurred on: Nov 14, 2016 -
FDA places clinical hold on Heparc-2004
Ticker: ARWR
Occurred on: Nov 08, 2016 -
Arrowhead Pharmaceuticals Prices $45 Million Private Offering at $5.90 per share
Ticker: ARWR
Occurred on: Aug 09, 2016 -
Arrowhead Pharma (ARWR) to Initiate Clinical Studies of ARC-521 in Hepatitis-B in 2016
Ticker: ARWR
Occurred on: Jun 10, 2016 -
Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521
Ticker: ARWR
Occurred on: Jun 09, 2016 -
Arrowhead (ARWR) Has Regulatory Submissions Planned for Phase 1/2 Trial Evaluating ARC-521 in Hepatitis-B by End of Q2 2016
Ticker: ARWR
Occurred on: Apr 28, 2016 -
Arrowhead Pharma (ARWR) Presents Data on ARC-520 in Treatment of Hepatitis B at The International Liver Congress 2016
Ticker: ARWR
Occurred on: Apr 13, 2016 -
Arrowhead Pharma (ARWR) Likely to Announce New Data from Ongoing Phase 2 Studies of ARC-520 in Hepatitis-B in 2016
Ticker: ARWR
Occurred on: Apr 13, 2016
Strategic Initiatives (ARWR)
-
Novartis(NVS) to acquire The Medicines Company(MDCO) for USD 9.7 bn, adding inclisiran, investigational cholesterol-lowering therapy
Tickers: NVS, ARWR, MDCO
Announcement Date: Nov 24, 2019
